Listed

Inovio Pharmaceuticals, Inc.

INONasdaqCIK 1055726HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$18.6m, Q2 FY2026
Net income−$6.0m, Q2 FY2026
Inovio Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.4Revenue, Q3 FY2023, three months to 2023-09-30$388.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure0.1Revenue, Q4 FY2023, three months to 2023-12-31$102.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure0.1Revenue, Q2 FY2024, three months to 2024-06-30$100.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure0.1Revenue, Q4 FY2024, three months to 2024-12-31$117.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$65.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Research and development$m15.5Research and development, Q3 FY2023, three months to 2023-09-30$15.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure17.3Research and development, Q4 FY2023, three months to 2023-12-31$17.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure20.9Research and development, Q1 FY2024, three months to 2024-03-31$20.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure23.1Research and development, Q2 FY2024, three months to 2024-06-30$23.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure18.7Research and development, Q3 FY2024, three months to 2024-09-30$18.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure12.9Research and development, Q4 FY2024, three months to 2024-12-31$12.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure16.1Research and development, Q1 FY2025, three months to 2025-03-31$16.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure14.5Research and development, Q2 FY2025, three months to 2025-06-30$14.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure13.3Research and development, Q3 FY2025, three months to 2025-09-30$13.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure10.3Research and development, Q4 FY2025, three months to 2025-12-31$10.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure14.1Research and development, Q1 FY2026, three months to 2026-03-31$14.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure10.8Research and development, Q2 FY2026, three months to 2026-06-30$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Operating income$m(35.6)Operating income, Q3 FY2023, three months to 2023-09-30−$35.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure(27.4)Operating income, Q4 FY2023, three months to 2023-12-31−$27.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(31.5)Operating income, Q1 FY2024, three months to 2024-03-31−$31.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure(33.2)Operating income, Q2 FY2024, three months to 2024-06-30−$33.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure(27.3)Operating income, Q3 FY2024, three months to 2024-09-30−$27.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure(20.4)Operating income, Q4 FY2024, three months to 2024-12-31−$20.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(25.1)Operating income, Q1 FY2025, three months to 2025-03-31−$25.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(23.1)Operating income, Q2 FY2025, three months to 2025-06-30−$23.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(21.2)Operating income, Q3 FY2025, three months to 2025-09-30−$21.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure(17.5)Operating income, Q4 FY2025, three months to 2025-12-31−$17.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(21.9)Operating income, Q1 FY2026, three months to 2026-03-31−$21.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(18.6)Operating income, Q2 FY2026, three months to 2026-06-30−$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Interest expense$m0.3Interest expense, Q3 FY2023, three months to 2023-09-30$313.5k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure0.3Interest expense, Q4 FY2023, three months to 2023-12-31$282.3k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-06, accession 0001055726-24-000011. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2024, three months to 2024-03-31$177.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure0.0Interest expense, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(33.9)Net income, Q3 FY2023, three months to 2023-09-30−$33.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure(25.0)Net income, Q4 FY2023, three months to 2023-12-31−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(30.5)Net income, Q1 FY2024, three months to 2024-03-31−$30.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure(32.2)Net income, Q2 FY2024, three months to 2024-06-30−$32.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure(25.2)Net income, Q3 FY2024, three months to 2024-09-30−$25.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure(19.4)Net income, Q4 FY2024, three months to 2024-12-31−$19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(19.7)Net income, Q1 FY2025, three months to 2025-03-31−$19.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(23.5)Net income, Q2 FY2025, three months to 2025-06-30−$23.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(45.5)Net income, Q3 FY2025, three months to 2025-09-30−$45.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure3.8Net income, Q4 FY2025, three months to 2025-12-31$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(19.7)Net income, Q1 FY2026, three months to 2026-03-31−$19.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(6.0)Net income, Q2 FY2026, three months to 2026-06-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Diluted EPS$ per share(1.52)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figurenot reported(1.31)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure(1.19)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure(0.89)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figurenot reported(0.51)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(0.61)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(0.87)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figurenot reported(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Basic EPS$ per share(1.52)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figurenot reported(1.31)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure(1.19)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure(0.89)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.89 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figurenot reported(0.51)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(0.61)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(0.87)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figurenot reported(0.28)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(0.07)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure

Balance sheet

Cash and equivalents$31.5m, Q2 FY2026
Shareholders' equity$4.4m, Q2 FY2026
Inovio Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m18.8Cash and equivalents, Q3 FY2023, at 2023-09-30$18.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure14.3Cash and equivalents, FY2023, at 2023-12-31$14.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-18, accession 0001055726-25-000012.Report this figure19.6Cash and equivalents, Q1 FY2024, at 2024-03-31$19.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure34.4Cash and equivalents, Q2 FY2024, at 2024-06-30$34.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure21.7Cash and equivalents, Q3 FY2024, at 2024-09-30$21.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure65.8Cash and equivalents, FY2024, at 2024-12-31$65.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure39.9Cash and equivalents, Q1 FY2025, at 2025-03-31$39.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure24.4Cash and equivalents, Q2 FY2025, at 2025-06-30$24.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure36.6Cash and equivalents, Q3 FY2025, at 2025-09-30$36.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure44.3Cash and equivalents, FY2025, at 2025-12-31$44.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure26.3Cash and equivalents, Q1 FY2026, at 2026-03-31$26.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure31.5Cash and equivalents, Q2 FY2026, at 2026-06-30$31.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Current assets$m175Current assets, Q3 FY2023, at 2023-09-30$174.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure153Current assets, FY2023, at 2023-12-31$153.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-18, accession 0001055726-25-000012.Report this figure112Current assets, Q1 FY2024, at 2024-03-31$111.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure118Current assets, Q2 FY2024, at 2024-06-30$117.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure91.3Current assets, Q3 FY2024, at 2024-09-30$91.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure97.8Current assets, FY2024, at 2024-12-31$97.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure71.9Current assets, Q1 FY2025, at 2025-03-31$71.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure52.7Current assets, Q2 FY2025, at 2025-06-30$52.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure55.2Current assets, Q3 FY2025, at 2025-09-30$55.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure61.1Current assets, FY2025, at 2025-12-31$61.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure39.4Current assets, Q1 FY2026, at 2026-03-31$39.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure39.9Current assets, Q2 FY2026, at 2026-06-30$39.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Total assets$m193Total assets, Q3 FY2023, at 2023-09-30$193.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure171Total assets, FY2023, at 2023-12-31$171.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-18, accession 0001055726-25-000012.Report this figure129Total assets, Q1 FY2024, at 2024-03-31$129.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure134Total assets, Q2 FY2024, at 2024-06-30$133.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure107Total assets, Q3 FY2024, at 2024-09-30$107.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure113Total assets, FY2024, at 2024-12-31$113.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure87.3Total assets, Q1 FY2025, at 2025-03-31$87.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure68.2Total assets, Q2 FY2025, at 2025-06-30$68.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure69.4Total assets, Q3 FY2025, at 2025-09-30$69.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure74.3Total assets, FY2025, at 2025-12-31$74.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure49.8Total assets, Q1 FY2026, at 2026-03-31$49.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure49.4Total assets, Q2 FY2026, at 2026-06-30$49.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Current liabilities$m43.7Current liabilities, Q3 FY2023, at 2023-09-30$43.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure42.6Current liabilities, FY2023, at 2023-12-31$42.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-18, accession 0001055726-25-000012.Report this figure23.4Current liabilities, Q1 FY2024, at 2024-03-31$23.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure26.4Current liabilities, Q2 FY2024, at 2024-06-30$26.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure23.5Current liabilities, Q3 FY2024, at 2024-09-30$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure35.3Current liabilities, FY2024, at 2024-12-31$35.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure27.3Current liabilities, Q1 FY2025, at 2025-03-31$27.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure31.7Current liabilities, Q2 FY2025, at 2025-06-30$31.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure69.8Current liabilities, Q3 FY2025, at 2025-09-30$69.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure43.7Current liabilities, FY2025, at 2025-12-31$43.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure37.9Current liabilities, Q1 FY2026, at 2026-03-31$37.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure39.9Current liabilities, Q2 FY2026, at 2026-06-30$39.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Total liabilities$m54.9Total liabilities, Q3 FY2023, at 2023-09-30$54.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure53.6Total liabilities, FY2023, at 2023-12-31$53.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-18, accession 0001055726-25-000012.Report this figure34.7Total liabilities, Q1 FY2024, at 2024-03-31$34.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure37.1Total liabilities, Q2 FY2024, at 2024-06-30$37.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure33.5Total liabilities, Q3 FY2024, at 2024-09-30$33.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure44.7Total liabilities, FY2024, at 2024-12-31$44.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure36.0Total liabilities, Q1 FY2025, at 2025-03-31$36.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure39.7Total liabilities, Q2 FY2025, at 2025-06-30$39.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure77.1Total liabilities, Q3 FY2025, at 2025-09-30$77.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure50.2Total liabilities, FY2025, at 2025-12-31$50.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure43.7Total liabilities, Q1 FY2026, at 2026-03-31$43.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure45.0Total liabilities, Q2 FY2026, at 2026-06-30$45.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m138Shareholders' equity, Q3 FY2023, at 2023-09-30$138.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure117Shareholders' equity, FY2023, at 2023-12-31$117.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-12, accession 0001055726-26-000008.Report this figure94.4Shareholders' equity, Q1 FY2024, at 2024-03-31$94.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure96.7Shareholders' equity, Q2 FY2024, at 2024-06-30$96.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure73.5Shareholders' equity, Q3 FY2024, at 2024-09-30$73.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure68.5Shareholders' equity, FY2024, at 2024-12-31$68.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure51.3Shareholders' equity, Q1 FY2025, at 2025-03-31$51.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure28.5Shareholders' equity, Q2 FY2025, at 2025-06-30$28.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure(7.7)Shareholders' equity, Q3 FY2025, at 2025-09-30−$7.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure24.1Shareholders' equity, FY2025, at 2025-12-31$24.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure6.1Shareholders' equity, Q1 FY2026, at 2026-03-31$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure4.4Shareholders' equity, Q2 FY2026, at 2026-06-30$4.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure

Cash flow

Operating cash flow−$18.0m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Inovio Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(29.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$29.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001055726-24-000052. Derived: 9-month figure less the 6-month figure.Report this figure(26.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$26.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(28.8)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$28.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure(28.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$28.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001055726-25-000055. Derived: 6-month figure less the 3-month figure.Report this figure(27.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$27.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001055726-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure(19.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(26.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$26.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(20.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$20.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001055726-26-000023. Derived: 6-month figure less the 3-month figure.Report this figure(21.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$21.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001055726-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure(19.4)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$19.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(21.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$21.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure(18.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$18.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001055726-26-000023. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001055726-24-000052. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-18, accession 0001055726-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$35.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure0.5Capital expenditure, Q2 FY2024, three months to 2024-06-30$452.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0001055726-25-000055. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001055726-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$59.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$30.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001055726-26-000023. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$68.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001055726-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$127.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001055726-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001055726-26-000023. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)81.62m, Q2 FY2026
Inovio Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares249Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30249,351,023 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001055726-23-000055.Report this figure21.5Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3121,536,476 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0001055726-24-000020.Report this figure22.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3022,029,486 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001055726-24-000046.Report this figure22.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3022,385,229 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001055726-24-000052.Report this figure23.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3123,291,512 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001055726-25-000026.Report this figure27.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3027,197,802 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001055726-25-000055.Report this figure28.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3028,140,497 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure38.6Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3138,613,653 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure38.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3038,830,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure52.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3052,168,694 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001055726-25-000063.Report this figure69.1Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3169,101,910 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001055726-26-000018.Report this figure81.6Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3081,619,113 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure

Shares outstanding: 103.40mShares outstanding, period not labelled, at 2026-08-10103,397,518 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001055726-26-000023.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. Listed shows no prices and gives no investment advice.